LIM-kinase 2 and Cofilin Phosphorylation Mediate Actin Cytoskeleton Reorganization Induced by Transforming Growth Factor-beta
Overview
Affiliations
Reorganization of the actin cytoskeleton in response to growth factor signaling, such as transforming growth factor beta (TGF-beta), controls cell adhesion, motility, and growth of diverse cell types. In Swiss3T3 fibroblasts, a widely used model for studies of actin reorganization, TGF-beta1 induced rapid actin polymerization into stress fibers and concomitantly activated RhoA and RhoB small GTPases. Consequently, dominant-negative RhoA and RhoB mutants blocked TGF-beta1-induced actin reorganization. Because Rho GTPases are known to regulate the activity of LIM-kinases (LIMK), we found that TGF-beta1 induced LIMK2 phosphorylation with similar kinetics to Rho activation. Cofilin and LIMK2 co-precipitated and cofilin became phosphorylated in response to TGF-beta1, whereas RNA interference against LIMK2 blocked formation of new stress fibers by TGF-beta1. Because the kinase ROCK1 links Rho GTPases to LIMK2, we found that inhibiting ROCK1 activity blocked completely TGF-beta1-induced LIMK2/cofilin phosphorylation and downstream stress fiber formation. We then tested whether the canonical TGF-beta receptor/Smad pathway mediates regulation of the above effectors and actin reorganization. Adenoviruses expressing constitutively activated TGF-beta type I receptor led to robust actin reorganization and Rho activation, whereas the constitutively activated TGF-beta type I receptor with mutated Smad docking sites (L45 loop) did not affect either actin organization or Rho activity. In line with this, ectopic expression of the inhibitory Smad7 inhibited TGF-beta1-induced Rho activation and cytoskeletal reorganization. Our data define a novel pathway emanating from the TGF-beta type I receptor and leading to regulation of actin assembly, via the kinase LIMK2.
Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies.
Sheikh K, Amjad M, Irfan M, Anjum S, Majeed T, Riaz M Onco Targets Ther. 2025; 18:233-262.
PMID: 39989503 PMC: 11846535. DOI: 10.2147/OTT.S493643.
LIM kinases in cardiovascular health and disease.
Lateef O, Foote C, Power G, Manrique-Acevedo C, Padilla J, Martinez-Lemus L Front Physiol. 2025; 15():1506356.
PMID: 39744707 PMC: 11688343. DOI: 10.3389/fphys.2024.1506356.
TGF-β2 enhances nanoscale cortex stiffness via condensation of cytoskeleton-focal adhesion plaque.
Duan M, Liu Y, Pi C, Zhao Y, Tian Y, Xie J Biophys J. 2024; 124(2):336-350.
PMID: 39645584 PMC: 11788479. DOI: 10.1016/j.bpj.2024.12.007.
TGF-β signaling in health, disease, and therapeutics.
Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C Signal Transduct Target Ther. 2024; 9(1):61.
PMID: 38514615 PMC: 10958066. DOI: 10.1038/s41392-024-01764-w.
Zheng B, Sun X, Zhang L, Qu G, Ren C, Yan P Braz J Med Biol Res. 2024; 57:e13152.
PMID: 38381883 PMC: 10880891. DOI: 10.1590/1414-431X2023e13152.